Phase II efficacy trial of pazopanib in nonclear cell metastatic renal cell cancer (mRCC): PINCR.

Brian A. Costello,Thai H. Ho,Gabriela Perez Burbano,David W. Hillman,Fernando Quevedo,Henry C. Pitot,Lance C. Pagliaro,Alan H. Bryce,Winston Tan,Richard W. Joseph,Bradley C. Leibovich,Erik P. Castle,Roxana S Dronca,Manish Kohli

Phase II efficacy trial of pazopanib in nonclear cell metastatic renal cell cancer (mRCC): PINCR.

2020

Brian A. Costello
Thai H. Ho
Gabriela Perez Burbano
David W. Hillman
Fernando Quevedo
Henry C. Pitot
Lance C. Pagliaro
Alan H. Bryce
Winston Tan
Richard W. Joseph
Bradley C. Leibovich
Erik P. Castle
Roxana S Dronca
Manish Kohli

696Background: A number of treatments for metastatic renal cell carcinoma (RCC) have been FDA approved since December, 2005. Trials evaluating these agents excluded non-clear cell histologies and t...

Keywords:

Oncology
Pathology
Pazopanib
Metastatic renal cell cancer
Internal medicine
Cell
Medicine
Renal cell carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations